PS.

NHS National Framework Agreement for Omalizumab

NHS EnglandcontractFind a Tender ↗Ref ocds-h6vhtk-058e04Procurement Act 2023SME suitableactive

Estimated value

—

Awarded value

—

Suppliers

3

Lots

1

1 awarded

Published

30 Dec 2025

Description

Project title: NHS National Framework for Omalizumab commencing 1st February 2026 Offer reference number: CM/TNS/25/5734 Period of framework: 1 February 2026 to 31 August 2027 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months. Published By: Medicines Procurement and Supply Chain - NHS Medicines Value & Access, NHS England

Scope

Reference
C382504
Commercial tool
Standalone contract
Contract dates
01 Feb 2026 to 31 Aug 2027
Possible extension to 31 Aug 2029

Option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months.

CPV classifications
33600000
Contract locations
North East England, United Kingdom
North West England, United Kingdom
East Midlands, United Kingdom
West Midlands, United Kingdom
East of England, United Kingdom
South East England, United Kingdom
South West England, United Kingdom
Particular suitability
Small and medium-sized enterprises (SME)

Award criteria

Criteria the buyer will use to evaluate bids.

NameDescriptionTypeWeighting
Price is not the only award criterionPrice is not the only award criterionprice100.00%

Submission & procedure

Procedure
Open procedure

Award details

Awarded supplier(s), contract period and value as published in the award notice.

Awarded value

—

Award date

—

Contract start

—

Contract end

—

Awarded to
CH
Celltrion Healthcare United Kingdom Limited
CH 11685363
MP
MERCURY PHARMACEUTICALS LIMITED
CH 02619880
NP
NOVARTIS PHARMACEUTICALS UK LIMITED
CH 00119006